With the emergence of data documenting the impact of TGFβ1 on the activation and function of various immune cell populations in both preclinical models and cancer patients, significant efforts have recently been made on developing therapeutic strategies for interfering with TGFβ1-mediated suppression of anti-tumor immune responses. Here, TGFB1 is linked to neoplasm.